# reload+after+2024-01-21 06:43:44.813694
address1§900 Chesapeake Drive
city§Redwood City
state§CA
zip§94063
country§United States
phone§650 665 9295
website§https://www.boltbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
fullTimeEmployees§94
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Randall C. Schatzman Ph.D.', 'age': 68, 'title': 'CEO & Director', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 829315, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edgar George Engleman M.D.', 'age': 77, 'title': 'Founder & Independent Director', 'yearBorn': 1946, 'fiscalYear': 2022, 'totalPay': 38750, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William P. Quinn', 'age': 52, 'title': 'CFO & Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 594560, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Grant  Yonehiro C.F.A., M.B.A.', 'age': 59, 'title': 'Chief Business Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 544707, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edith A. Perez M.D.', 'age': 66, 'title': 'Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 668320, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Wesley  Burwell', 'title': 'VP & Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nathan  Ihle Ph.D.', 'title': 'Senior Vice President of Pharmaceutical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.858
priceToSalesTrailing12Months§6.2766633
currency§USD
dateShortInterest§1702598400
forwardEps§-1.63
exchange§NMS
quoteType§EQUITY
shortName§Bolt Biotherapeutics, Inc.
longName§Bolt Biotherapeutics, Inc.
firstTradeDateEpochUtc§1612535400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§dff93495-0732-3bf9-90c2-03f27dac1fe3
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§1.25
targetMeanPrice§4.54
targetMedianPrice§4.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§6.534
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
